Merkel Cell Carcinoma: Rare Aggressive Skin Cancer

Merkel cell carcinoma is a rare, aggressive neuroendocrine skin cancer accounting for <1% of skin cancers but responsible for 10-15% of skin cancer deaths due to high metastatic propensity (25-50% regional/systemic metastases at diagnosis). This malignancy arises from Merkel cells (touch-receptor cells in basal epidermis) and presents clinically as rapidly enlarging, firm nodules, frequently mistaken for benign lesions (cysts, lipomas, melanoma), creating diagnostic delays. Merkel cell polyomavirus (MCPyV) integration is detected in 75-85% of cases, with viral oncoprotein T-antigens driving malignant transformation. Prognosis is substantially worse than other cutaneous malignancies: 5-year survival rates of 50-60% overall, declining to 10-25% for stage IV disease, though emerging immunotherapy approaches show promise for improving outcomes.

Epidemiology and Etiology

Merkel cell carcinoma incidence is 0.2-0.5 per 100,000 person-years, increasing with age (median presentation age 70-75 years). Risk factors include: (1) sun exposure (associated with chronically exposed anatomic sites); (2) immunosuppression (40-50 fold increased incidence in HIV/AIDS, organ transplant recipients); (3) fair skin phototype; and (4) advanced age.

Merkel cell polyomavirus is detected in 75-85% of MCC cases, with integrated viral genome producing T-antigens (large T-antigen, small t-antigen) driving cellular transformation. MCPyV-negative tumors (15-25% of cases) typically show high tumor mutational burden, suggesting alternative carcinogenic pathways. UV-induced mutations are evident in both MCPyV-positive and negative tumors, implicating sun exposure in pathogenesis.

Clinical Presentation

Typical presentation involves solitary, rapidly enlarging (weeks-to-months), firm to hard nodule, frequently skin-colored, reddish, or violaceous. Common locations include: (1) head/neck (30-50%); (2) upper extremities (25-35%); (3) lower extremities (20-30%); and (4) genitalia (5-10%).

Clinical presentation frequently mimics benign lesions (cyst, lipoma, epidermal inclusion cyst), resulting in delayed diagnosis. Imaging characteristics include hypoechoic nodule on ultrasound or heterogeneous enhancement on MRI. However, histopathology remains essential for diagnosis as clinical/imaging features alone are insufficiently specific.

Rapid growth, local pain or tenderness, and large size (>3 cm) raise suspicion for MCC. Regional lymphadenopathy at diagnosis is present in 30-40%, indicating nodal metastases. Distant metastases at diagnosis occur in 10-15% of patients.

Histopathology and Staging

Histology: Dense infiltrate of small, round neuroendocrine cells with scant cytoplasm and hyperchromatic nuclei. Cells demonstrate high mitotic rate (>8 mitoses/10 high-power fields typical). Immunohistochemistry is essential: CK-20 positive (paranuclear dot staining pattern is characteristic), synaptophysin positive, chromogranin positive, neuron-specific enolase positive. CK-20 positivity distinguishes MCC from small cell carcinoma (CK-20 negative).

Staging: Stage I: ≤2 cm without nodal/distant metastases. Stage II: >2 cm without nodal involvement. Stage III: Any tumor with regional nodal metastases. Stage IV: Distant metastases. Five-year survival: Stage I 85%; Stage II 70%; Stage III 35%; Stage IV 10-25%.

Treatment and Outcomes

Surgery: Wide local excision with 1-2 cm margins is standard. Sentinel lymph node biopsy is strongly recommended as SLN status substantially influences staging and adjuvant therapy decisions. Complete lymph node dissection is performed if SLN is positive.

Radiation Therapy: Adjuvant radiation (50-60 Gy to primary site and regional nodes) reduces locoregional recurrence by 50-70% in prospective trials. Most centers recommend adjuvant radiation for all stage II-III MCC given high recurrence risk and improved locoregional control.

Immunotherapy: Checkpoint inhibitors (anti-PD-1: avelumab, nivolumab; anti-CTLA-4: ipilimumab) show dramatic responses in advanced/metastatic MCC, with response rates 60-80% and durable remissions in 30-50% of treated patients. Adjuvant immunotherapy is increasingly employed for stage III disease and is under investigation for stage II.

Systemic Chemotherapy: For unresectable/metastatic disease, platinum-etoposide chemotherapy achieves response rates 50-70% but responses are typically short-lived (median 4-6 months). Immunotherapy is increasingly preferred over chemotherapy given superior durability of response.

Surveillance and Prognosis

Post-treatment surveillance includes clinical examination every 3 months for 2 years, then every 6 months. Imaging (ultrasound or cross-sectional imaging) may detect locoregional recurrence earlier than clinical examination. However, survival remains guarded; 50% of patients develop recurrent disease within 5 years despite complete initial treatment.

FAQ

Q: How serious is Merkel cell carcinoma?
A: Highly aggressive: 50% 5-year survival overall (vs. >95% for BCC, 95% for early SCC, 90% for early melanoma). 25-50% present with metastases at diagnosis.

Q: Is Merkel cell carcinoma curable?
A: Yes, if detected early (stage I). Stage I shows 85% 5-year survival. Advanced disease (stage IV) shows only 10-25% 5-year survival, though immunotherapy is improving outcomes.

Q: Do I need lymph node biopsy?
A: Strongly recommended. SLN status determines stage and guides adjuvant therapy decisions. Positive SLN indicates stage III disease warranting adjuvant radiation and potentially immunotherapy.

Q: What is the treatment for advanced Merkel cell carcinoma?
A: Checkpoint inhibitor immunotherapy (avelumab, nivolumab) shows superior outcomes compared to chemotherapy, with response rates 60-80% and durable remissions in 30-50%.

References